卵巢刺激中高纯度人绝经期促性腺激素较重组卵泡刺激素血清孕酮更低:一项随机对照试验
该随机对照试验纳入112名卵母细胞捐献者,比较r-FSH与hp-HMG方案。hp-HMG组触发日血清孕酮为0.46 ± 0.27 ng/ml,低于r-FSH组的0.68 ± 0.50 ng/ml(P = 0.010)。hp-HMG通过增强Δ4途径使孕酮降低,可能有利于新鲜胚胎移植。
要点
- hp-HMG组触发日血清孕酮低于r-FSH组(0.46 ± 0.27 vs 0.68 ± 0.50 ng/ml,P = 0.010)。
- hp-HMG增强孕烯醇酮向雄烯二酮转化,降低孕酮水平。
- 两组成熟卵母细胞数相似(16.5 ± 7.5 vs 17.5 ± 7.9,P = 0.49)。
核心结论
- hp-HMG可能通过不同卵泡类固醇生成途径防止卵泡晚期孕酮升高,且不依赖卵巢反应。
研究设计与样本
- 随机对照试验,纳入112名卵母细胞捐献者,随机接受r-FSH(n=56)或hp-HMG(n=56)225 IU/天,于2016年10月至2018年6月在一所大学附属私立不孕症诊所进行。
主要发现
- 触发日血清孕酮hp-HMG组0.46 ± 0.27 ng/ml vs r-FSH组0.68 ± 0.50 ng/ml(P = 0.010)。
- 刺激第6天和第8天孕酮差异也显著。
- 触发日血清雄烯二酮hp-HMG组3.0 ± 1.4 ng/ml vs r-FSH组2.4 ± 1.1 ng/ml(P = 0.015)。
- 孕烯醇酮:雄烯二酮比值hp-HMG组显著更高(P = 0.012,第6、8天及触发日)。
- 卵泡液中雌二醇、FSH、LH、脱氢表雄酮、雄烯二酮和睾酮hp-HMG组显著高于r-FSH组。
临床怎么用
- 作者认为,对于计划新鲜胚胎移植且存在卵泡晚期孕酮升高风险的患者,可考虑使用hp-HMG。
局限性
- 所有女性年轻、非不孕、BMI正常且卵巢储备良好,其他患者亚群结果可能不同。
- 免疫分析法激素检测存在批内变异,可能影响结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does ovarian stimulation with highly purified (hp)-HMG protect from elevated progesterone in the follicular phase compared to recombinant FSH (r-FSH) cycles through a different regulation of follicular steroidogenesis? SUMMARY ANSWER: hp-HMG enhanced the Δ4 pathway from pregnenolone to androstenodione leading to lower serum progesterone at the end of the cycle, while r-FSH promoted the conversion of pregnenolone to progesterone causing higher follicular phase progesterone levels. WHAT IS KNOWN ALREADY: Elevated progesterone in the follicular phase has been related to lower clinical outcome in fresh IVF cycles. Progesterone levels are positively correlated to ovarian response, and some studies have shown that when r-FSH alone is used for ovarian stimulation serum progesterone levels on the day of triggering are higher than when hp-HMG is given. Whether this is caused by a lower ovarian response in hp-HMG cycles or to a difference in follicular steroidogenesis in the two ovarian stimulation regimens has not been well characterized. STUDY DESIGN, SIZE, DURATION: A randomized controlled trial including 112 oocyte donors undergoing ovarian stimulation with GnRH antagonists and 225 IU/day of r-FSH (n = 56) or hp-HMG (n = 56) was carried out in a university-affiliated private infertility clinic. Subjects were recruited between October 2016 and June 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: The women were aged 18-35 years with a regular menstrual cycle (25-35 days) and normal ovarian reserve (serum anti-Müllerian hormone (AMH) = 10-30 pMol/l) undergoing ovarian stimulation for oocyte donation. FSH, LH, estradiol (E2), estrone, progesterone, pregnenolone, 17-OH-progesterone, androstenodione, dehidroepiandrostenodione, and testosterone were determined on stimulation Days 1, 4, 6, and 8 and on day of triggering in serum and in follicular fluid. Samples were frozen at -20°C until assay. Total exposures across the follicular phase were compared by polynomic extrapolation. MAIN RESULTS AND THE ROLE OF CHANCE: Subjects in both groups were comparable in terms of age, BMI, and AMH levels. Ovarian response was also similar: 17.5 ± 7.9 (mean ± SD) versus 16.5 ± 7.5 oocytes with r-FSH and hp-HMG, respectively (P = 0.49). Serum progesterone (ng/ml) on day of trigger was 0.46 ± 0.27 in the hp-HMG group versus 0.68 ± 0.50 in the r-FSH group (P = 0.010). Differences for progesterone were also significant on stimulation days 6 and 8. The pregnenolone: progesterone ratio was significantly increased in the r-FSH group from stimulation day 8 to the day of trigger (P = 0.019). Serum androstenodione (ng/ml) on day of trigger was 3.0 ± 1.4 in the hp-HMG group versus 2.4 ± 1.1 in the r-FSH group (P = 0.015). Differences in adrostenodione were also significant on stimulation Day 8. The pregnenolone:androstenodione ratio was significantly higher in the hp-HMG group (P = 0.012) on Days 6 and 8 and trigger. There were no other significant differences between groups. Follicular fluid E2, FSH, LH, dehidroepioandrostenodione, androstenodione, and testosterone were significantly higher in the hp-HMG than r-FSH group. No differences were observed for progesterone, estrone, 17-OH-progesterone, and pregnenolone in follicular fluid. LIMITATIONS, REASONS FOR CAUTION: All women included in the study were young, not infertile, and had a normal BMI and a good ovarian reserve. The findings might be different in other patient subpopulations. Hormone analyses with immunoassays are subject to intra-assay variations that may influence the results. WIDER IMPLICATIONS OF THE FINDINGS: Stimulation with hp-HMG may prevent progesterone elevation at the end of the follicular phase because of a different follicular steroidogenesis pathway, regardless of ovarian response. This should be considered, particularly in patients at risk of having high progesterone levels at the end of the follicular phase when a fresh embryo transfer is planned. STUDY FUNDING/COMPETING INTEREST(S): Roche Diagnostics provided unrestricted funding for all serum and follicular fluid hormone determinations. J.L.R., M.M., and A.P. have nothing to declare. E.B. has received consulting fees from Ferring, Merck, Gedeon Richter, and Roche and has participated in a research cooperation with Gedeon-Richter. In addition, the author has participated in speakers' bureau and received fees from Ferring, Gedeon Richter, Merck, and Roche. P.A. has received consulting fees from MSD and has participated in speakers' bureau and received fees from Ferring. P.A. also declares travel/meeting support from MSD. E.L. has received consulting fees from Ferring and MSD. In addition, the author has participated in a research cooperation with Gedeon-Richter. Also, the author has participated in speakers' bureau and received fees from Ferring and IBSA, as well as travel/meeting support from IBSA and Gedeon Richter. E.B., P.A., and E.L. also own stocks in IVIRMA Valencia. TRIAL REGISTRATION NUMBER: NCT: NCT02738580. TRIAL REGISTER DATE: 19 February 2016. DATE OF FIRST PATIENT’S ENROLMENT: 03 October 2016.
引用
- Bosch E, Alamá P, Romero JL, et al. Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial. Hum Reprod. 2024. PMID: 38037188. doi:10.1093/humrep/dead251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。